Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAP07: Gemcitabine +/- Chemoradiotherapy and +/- Erlotinib in Pancreatic Cancer
NCT00634725Phase 3Completed
- Sponsor
- GERCOR
- Start
- Feb 2008
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by GERCOR. Started Feb 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00634725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634725.